Sirnaomics Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
37
- Stock Symbol
-
02257
- Investments
-
4
- Share Price
-
$0.52
- (As of Friday Closing)
Sirnaomics General Information
Description
Sirnaomics Ltd is a therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of drugs for indications with medical needs and large market opportunities. The Group's operations and non-current assets are located at the United States of America and the mainland of the People's Republic of China. All of the company's revenue is derived from the mainland of the People's Republic of China (the PRC). The pipeline includes: STP705, STP707, STP355, STP369, STP705, STP122G, STP125G, and STP144G.
Contact Information
Website
www.sirnaomics.comCorporate Office
- 401 Professional Drive
- Suite 280
- Gaithersburg, MD 20879
- United States
Corporate Office
- 401 Professional Drive
- Suite 280
- Gaithersburg, MD 20879
- United States
Sirnaomics Stock Performance
As of 13-Nov-2026, Sirnaomics’s stock price is $0.52. Its current market cap is $57.5M with 111M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.52 | $0.52 | $0.45 - $1.38 | $57.5M | 111M | 41.5K | -$0.11 |
Sirnaomics Financials Summary
As of 30-Jun-2026, Sirnaomics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 45,387 | 91,113 | 27,283 | 370,270 |
| Revenue | 0 | 0 | 1,778 | 0 |
| EBITDA | (10,372) | (11,985) | (43,696) | (78,804) |
| Net Income | (10,614) | (14,403) | (51,383) | (78,691) |
| Total Assets | 13,417 | 20,605 | 28,329 | 75,787 |
| Total Debt | 2,610 | 9,314 | 8,058 | 8,845 |
Sirnaomics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sirnaomics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Sirnaomics Comparisons
Industry
Financing
Details
Sirnaomics Competitors (45)
One of Sirnaomics’s 45 competitors is Agenus, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Affimed | Formerly VC-backed | Mannheim, Germany | ||||
| ImmunityBio | Formerly VC-backed | San Diego, CA | ||||
| Arcturus Therapeutics Holdings | Formerly VC-backed | San Diego, CA | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom |
Sirnaomics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sirnaomics Patents
Sirnaomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025259875-A1 | Novel antibody oligonucleotide drug conjugates containing gemcitibine for pharmaceutical compositions and related methods of use and treatment | Pending | 12-Jun-2024 | ||
| US-20260265754-A1 | Chk1-targeting sirnas chemically modified with gemcitabine | Pending | 02-Apr-2024 | ||
| WO-2025212732-A1 | Chk1-targeting sirnas chemically modified with gemcitabine | Pending | 02-Apr-2024 | ||
| WO-2025019860-A1 | Oligonucleotide constructs with improved function and therapeutics | Inactive | 20-Jul-2023 | ||
| WO-2024254589-A2 | Products and compositions | Inactive | 09-Jun-2023 | A61K31/7125 |
Sirnaomics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sirnaomics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sirnaomics Investments (4)
Sirnaomics’s most recent deal was a Early Stage VC with RabPharma. The deal was made on 10-Sep-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| RabPharma | 10-Sep-2025 | Early Stage VC | Drug Discovery | ||
| Sagesse Bio | 31-Jul-2024 | Joint Venture | Drug Discovery | ||
| RNAimmune | 29-Mar-2022 | Early Stage VC | Drug Discovery | ||
| RNAimmune | 21-Apr-2021 | Seed Round | Drug Discovery |
Sirnaomics ESG
Risk Overview
Risk Rating
Updated May, 31, 2023
26.74 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,201
Rank
Percentile
Pharmaceuticals
Industry
of 863
Rank
Percentile
Biotechnology
Subindustry
of 373
Rank
Percentile
Sirnaomics Exits (1)
Sirnaomics’s most recent exit was on 31-Jul-2024 from Sagesse Bio. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Sagesse Bio | 31-Jul-2024 | Completed |
|
Sirnaomics FAQs
-
When was Sirnaomics founded?
Sirnaomics was founded in 2007.
-
Where is Sirnaomics headquartered?
Sirnaomics is headquartered in Gaithersburg, MD.
-
What is the size of Sirnaomics?
Sirnaomics has 37 total employees.
-
What industry is Sirnaomics in?
Sirnaomics’s primary industry is Drug Discovery.
-
Is Sirnaomics a private or public company?
Sirnaomics is a Public company.
-
What is Sirnaomics’s stock symbol?
The ticker symbol for Sirnaomics is 02257.
-
What is the current stock price of Sirnaomics?
As of 13-Nov-2026 the stock price of Sirnaomics is $0.52.
-
What is the current market cap of Sirnaomics?
The current market capitalization of Sirnaomics is $57.5M.
-
Who are Sirnaomics’s competitors?
Agenus, Affimed, ImmunityBio, Arcturus Therapeutics Holdings, and Immunocore Holdings are some of the 45 competitors of Sirnaomics.
-
What is Sirnaomics’s annual earnings per share (EPS)?
Sirnaomics’s EPS for 12 months was -$0.11.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
